ASH News Daily 2017 - Issue 1 - A-18
SAT 2017
ASHN
News
ewS D
Daily
Aily
ASH
PageA-18
B-6
Page
Sunday, December
December 9,
Saturday,
9, 2012
2017
®
ASH Live: Today's Remote Session Viewing Schedule
ASH Central: Hall B1
7:30 - 9:00 a.m.
9:30 - 11:00 a.m.
Noon - 1:30 p.m.
12:30 - 1:30 p.m.
2:00 - 3:30 p.m. 4:00 - 5:30 p.m.
Next-Generation
Sequencing in Routine
Diagnostics: Are We
There Yet?
Genetic Pathways
That Disrupt
Hematopoietic Stem
Cell Function in
Inherited Bone
Marrow Failure
623. Mantle Cell,
Follicular, and Other
Indolent B Cell
Lymphoma-
Clinical Studies: Mantle Cell Lymphoma,
New Therapies
Ham-Wasserman
Lecture
626. Aggressive Lymphoma (Diffuse Large B
Cell and Other Aggressive B Cell Non- Hodgkin
Lymphomas)-Results
from Prospective Clinical
Trials
Hematopoietic Stem
Cell Generation:
Reprogramming and
Expansion
Special Education
Session on New
ASH Clinical Practice
Guidelines on Venous
Thromboembolism
Primary
Immunodeficiencies
From Childhood to
Adulthood
703. Adoptive
Immunotherapy:
Immune Therapeutics
for Hematologic
Cancers: Artificial
Receptors and Beyond
Genetic Pathways
That Disrupt
Hematopoietic Stem
Cell Function in
Inherited Bone
Marrow Failure
Primary
Immunodeficiencies
From Childhood to
Adulthood
621. Lymphoma-
Genetic/Epigenetic
Biology: Genomic
Characterization
of Lymphoma and
Beyond
625. Lymphoma:
Pre-Clinical-
Chemotherapy and
Biologic Agents
506. Hematopoiesis
and Stem Cells: Microenvironment, Cell
Adhesion, and Stromal
Stem Cells
627. Aggressive
Lymphoma (Diffuse
Large B-Cell and Other
Aggressive B-Cell NonHodgkin Lymphomas)
641. CLL: Biology
and Pathophysiology,
excluding Therapy:
Therapeutic Resistance
in CLL
Chronic Myeloid
Leukemia: Where
Are We in the
Current TKI Era?
Clonal Evolution in
Myeloid Malignancies
637. Myelodysplastic
Syndromes-Clinical
Studies: Predicting
Drug Response Using
Novel Genomic Algorithms
Advances in Cellular
Immunotherapy for
Lymphoid Malignancies
Special ASH
Symposium on CAR-T
Channel 5
The Expanding Role
of Immunotherapy
in Non-Hodgkin
Lymphoma
Novel Therapeutics in
Myeloma
614. Acute Lymphoblastic Leukemia:
Therapy, excluding
Transplantation:
Therapy, Excluding
CAR-T Cell
Controversies in Myeloma
Indolent Lymphoma:
How Understanding
Disease Biology Is
Influencing Clinical
Decision-Making
Channel 6
Acute Myeloid
Leukemia: How Can
We Improve Upon
"Standard" Therapy?
Advances in Cellular
Immunotherapy
for Lymphoid
Malignancies
615. Acute Myeloid
Leukemia: Commercially Available
Therapy, excluding
Transplantation: Innovative AML Treatment
with Approved Agents
617. Acute Myeloid
Leukemia: Biology,
Cytogenetics, and
Molecular Markers
in Diagnosis and
Prognosis
617. Acute Myeloid
Leukemia: Biology,
Cytogenetics, and
Molecular Markers in
Diagnosis and
Prognosis
Special Symposium on
Quality
602. Disordered Gene
Expression in
Hematologic Malignancy, including
Disordered Epigenetic
Regulation
636. Myelodysplastic
Syndromes-Basic
and Translational
Studies
636. Myelodysplastic
Syndromes-Basic
and Translational Studies
634. Myeloproliferative Syndromes:
Clinical: Biologic- Clinical Correlative Studies
in MPNs, Including
Transplant
634. Myeloproliferative Syndromes: Clinical: Phase I/II Trials of
Novel Agents in MPNs
The Yin and Yang of
Myeloma: Understanding and Harnessing
Normal Plasma Cell
Biology to Better Treat
Myeloma
612. Acute Lymphoblastic Leukemia:
Clinical Studies:
Advances in the
Treatment of ALL
Iron Trafficking: Ins
and Outs in Organelles, Organs, and
Organisms
723. Clinical Allogeneic and Autologous
Transplantation: Late
Complications and
Approaches to Disease
Recurrence:
618. Acute Lymphoblastic Leukemia:
Biology, Cytogenetics,
and Molecular Markers in Diagnosis and
Prognosis
Special Scientific Symposium on Hot Topics
in Hematology: New
Pathways Linking Hematopoiesis, Thrombosis, and Cardiovascular Disease
Special Scientific
Symposium on Understanding and Modulating the DNA Damage
Response
AML MATTERS: A
Multidisciplinary Approach To Testing and
Diagnosis, Evaluation
of Risk, and Personalized Treatment Selection
Channel 11
Evolving Strategies
in Aggressive B-Cell
Lymphoma
Management of Sickle
Cell Disease: Present
and Future
Acute Lymphocytic
Leukemia: New
Approaches in Management
Novel Epigenetic
Modifications in
Cancer and
Development
Channel 12
651. Myeloma: Biology
and Pathophysiology,
excluding Therapy
Targeting T Cell
Exhaustion
Myelodysplastic Syndromes: Understanding
the Current Treatment
Landscape
The Yin and Yang of
Myeloma: Understanding and Harnessing
Normal Plasma Cell
Biology to Better Treat
Myeloma
Channel 1
Channel 2
Channel 3
Channel 4
Channel 7
Channel 8
Channel 9
Channel 10
Evolving Approaches
to Gene Therapy for
Blood Diseases
New Approaches to
Understanding Microbial Immune System
Interactions
Table of Contents for the Digital Edition of ASH News Daily 2017 - Issue 1
ASH News Daily 2017 - Issue 1 - A-1
ASH News Daily 2017 - Issue 1 - A-2
ASH News Daily 2017 - Issue 1 - A-3
ASH News Daily 2017 - Issue 1 - A-4
ASH News Daily 2017 - Issue 1 - A-5
ASH News Daily 2017 - Issue 1 - A-6
ASH News Daily 2017 - Issue 1 - A-7
ASH News Daily 2017 - Issue 1 - A-8
ASH News Daily 2017 - Issue 1 - A-9
ASH News Daily 2017 - Issue 1 - A-10
ASH News Daily 2017 - Issue 1 - A-11
ASH News Daily 2017 - Issue 1 - A-12
ASH News Daily 2017 - Issue 1 - A-13
ASH News Daily 2017 - Issue 1 - A-14
ASH News Daily 2017 - Issue 1 - A-15
ASH News Daily 2017 - Issue 1 - A-16
ASH News Daily 2017 - Issue 1 - A-17
ASH News Daily 2017 - Issue 1 - A-18
ASH News Daily 2017 - Issue 1 - A-19
ASH News Daily 2017 - Issue 1 - A-20
ASH News Daily 2017 - Issue 1 - A-21
ASH News Daily 2017 - Issue 1 - A-22
ASH News Daily 2017 - Issue 1 - A-23
ASH News Daily 2017 - Issue 1 - A-24
ASH News Daily 2017 - Issue 1 - A-25
ASH News Daily 2017 - Issue 1 - A-26
ASH News Daily 2017 - Issue 1 - A-27
ASH News Daily 2017 - Issue 1 - A-28
ASH News Daily 2017 - Issue 1 - B-1
ASH News Daily 2017 - Issue 1 - B-2
ASH News Daily 2017 - Issue 1 - B-3
ASH News Daily 2017 - Issue 1 - B-4
ASH News Daily 2017 - Issue 1 - B-5
ASH News Daily 2017 - Issue 1 - B-6
ASH News Daily 2017 - Issue 1 - B-7
ASH News Daily 2017 - Issue 1 - B-8
ASH News Daily 2017 - Issue 1 - B-9
ASH News Daily 2017 - Issue 1 - B-10
ASH News Daily 2017 - Issue 1 - B-11
ASH News Daily 2017 - Issue 1 - B-12
ASH News Daily 2017 - Issue 1 - B-13
ASH News Daily 2017 - Issue 1 - B-14
ASH News Daily 2017 - Issue 1 - B-15
ASH News Daily 2017 - Issue 1 - B-16
ASH News Daily 2017 - Issue 1 - B-17
ASH News Daily 2017 - Issue 1 - B-18
ASH News Daily 2017 - Issue 1 - B-19
ASH News Daily 2017 - Issue 1 - B-20
ASH News Daily 2017 - Issue 1 - B-21
ASH News Daily 2017 - Issue 1 - B-22
ASH News Daily 2017 - Issue 1 - B-23
ASH News Daily 2017 - Issue 1 - B-24
ASH News Daily 2017 - Issue 1 - B-25
ASH News Daily 2017 - Issue 1 - B-26
ASH News Daily 2017 - Issue 1 - B-27
ASH News Daily 2017 - Issue 1 - B-30
ASH News Daily 2017 - Issue 1 - B-31
ASH News Daily 2017 - Issue 1 - B-32
ASH News Daily 2017 - Issue 1 - B-33
ASH News Daily 2017 - Issue 1 - B-34
ASH News Daily 2017 - Issue 1 - B-35
ASH News Daily 2017 - Issue 1 - B-36
ASH News Daily 2017 - Issue 1 - B-37
ASH News Daily 2017 - Issue 1 - B-38
ASH News Daily 2017 - Issue 1 - B-39
ASH News Daily 2017 - Issue 1 - B-40
ASH News Daily 2017 - Issue 1 - B-41
ASH News Daily 2017 - Issue 1 - B-42
ASH News Daily 2017 - Issue 1 - B-43
ASH News Daily 2017 - Issue 1 - B-44
ASH News Daily 2017 - Issue 1 - B-45
ASH News Daily 2017 - Issue 1 - B-46
ASH News Daily 2017 - Issue 1 - B-47
ASH News Daily 2017 - Issue 1 - B-48
ASH News Daily 2017 - Issue 1 - B-49
ASH News Daily 2017 - Issue 1 - B-50
ASH News Daily 2017 - Issue 1 - B-51
ASH News Daily 2017 - Issue 1 - B-52
ASH News Daily 2017 - Issue 1 - B-53
ASH News Daily 2017 - Issue 1 - B-54
ASH News Daily 2017 - Issue 1 - B-55
ASH News Daily 2017 - Issue 1 - B-56
ASH News Daily 2017 - Issue 1 - C-1
ASH News Daily 2017 - Issue 1 - C-2
ASH News Daily 2017 - Issue 1 - C-3
ASH News Daily 2017 - Issue 1 - C-4
ASH News Daily 2017 - Issue 1 - C-5
ASH News Daily 2017 - Issue 1 - C-6
ASH News Daily 2017 - Issue 1 - C-7
ASH News Daily 2017 - Issue 1 - C-8
ASH News Daily 2017 - Issue 1 - C-9
ASH News Daily 2017 - Issue 1 - C-10
ASH News Daily 2017 - Issue 1 - C-11
ASH News Daily 2017 - Issue 1 - C-12
ASH News Daily 2017 - Issue 1 - C-13
ASH News Daily 2017 - Issue 1 - C-14
ASH News Daily 2017 - Issue 1 - C-15
ASH News Daily 2017 - Issue 1 - C-16
ASH News Daily 2017 - Issue 1 - C-17
ASH News Daily 2017 - Issue 1 - C-18
ASH News Daily 2017 - Issue 1 - C-19
ASH News Daily 2017 - Issue 1 - C-20
ASH News Daily 2017 - Issue 1 - C-21
ASH News Daily 2017 - Issue 1 - C-22
ASH News Daily 2017 - Issue 1 - C-23
ASH News Daily 2017 - Issue 1 - C-24
ASH News Daily 2017 - Issue 1 - C-25
ASH News Daily 2017 - Issue 1 - C-26
ASH News Daily 2017 - Issue 1 - C-27
ASH News Daily 2017 - Issue 1 - C-28
ASH News Daily 2017 - Issue 1 - C-29
ASH News Daily 2017 - Issue 1 - C-30
ASH News Daily 2017 - Issue 1 - C-31
ASH News Daily 2017 - Issue 1 - C-32
https://www.nxtbookmedia.com